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Cell cycleIt is now recognized that in addition to its activity upon erythroid progenitor cells, erythropoietin (Epo)
is capable of stimulating survival of different non-erythroid cells. Since stimulation of erythropoiesis is
unwanted for neuroprotection, Epo-like compounds with a more selective action are under investigation.
Although the carbamylated derivative of erythropoietin (cEpo) has demonstrated non-hematopoietic tissue
protection without erythropoietic effect, little is known about differential mechanisms between Epo and
cEpo. Therefore, we investigated signaling pathways which play a key role in Epo-induced proliferation.
Here we show that cEpo blocked FOXO3a phosphorylation, allowing expression of downstream target
p27kip1 in UT-7 and TF-1 cells capable of erythroid differentiation. This is consistent with the involvement
of cEpo in slowing down G1-to-S-phase progression compared with the effect of Epo upon cell cycle. In
contrast, similar antiapoptotic actions of cEpo and Epo were observed in neuronal SH-SY5Y cells. Inhibition
and competition assays suggest that Epo may act through both, the homodimeric (EpoR/EpoR) and the
heterodimeric (EpoR/βcR) receptors in neuronal SH-SY5Y cells and probably in the TF-1 cell type as well.
Results also indicate that cEpo needs both the EpoR and βcR subunits to prevent apoptosis of neuronal
cells. Based on evidence suggesting that cell proliferation pathways were involved in the differential effect
of Epo and cEpo, we went forward to studying downstream signals. Here we provide the ﬁrst evidence
that unlike Epo, cEpo failed to induce FOXO3a inactivation and subsequent p27kip1 downregulation, which
is clearly shown in the incapacity of cEpo to induce erythroid cell growth.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Erythropoietin (Epo) is a pleiotropic cytokine originally identiﬁed
for its role in erythropoiesis. The requirement of Epo starts at the
mature burst-forming unit erythroid (BFU-E) stage, and is especially
important at the colony-forming unit erythroid (CFU-E). That is why
during erythroid differentiation the erythropoietin receptor (EpoR)
is expressed at the BFU-E stage, peaks at the CFU-E/proerythroblast
stages, and subsequently decreases to less detectable levels. One ofmylated erythropoietin; CFU-E,
de; Epo, erythropoietin; EpoR,
-CSF, granulocyte-macrophage
, 3-(4,5-dimethylthiazol-2-yl)-
polymerase 1; PBS, phosphate-
nositol 3-kinase; SEM, standard
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. Tel./fax: +54 11 4576 3342.
l rights reserved.the earliest detectable signaling events elicited upon EpoR activation is
the tyrosine phosphorylation of several intracellular proteins. Owing
to the fact that EpoR lacks a kinase domain within its cytoplasmic
region, the protein tyrosine kinase function is carried out by the Janus
kinase 2 (Jak2) associated to the receptor, which serves as the main
kinase involved in Epo signal transduction activating survival and prolif-
eration cell programs.
Interestingly, EpoR expression and Epo responses were also ob-
served in non-hematopoietic cell types. These ﬁndings can explain
why, in addition to having activity upon erythroid progenitors, Epo
is capable of stimulating survival and/or proliferation of different
non-erythroid cells [1–4].
Since stimulation of erythropoiesis is unwanted for neuroprotection,
Epo-like compoundswithmore selective action are under investigation.
One such compound, the carbamylated erythropoietin (cEpo), has been
experimentally demonstrated to providenon-hematopoietic tissue pro-
tection without erythropoietic effect [5–8].
A major discovery concerning extra-hematopoietic actions of Epo
was the identiﬁcation of a different type of receptor in non-erythroid
tissues, particularly in nerve cells [5,6]. These reports suggest that in
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mers, whereas in non-erythroid tissues Epo activity is mediated by
a heterodimer consisting of one Epo receptor monomer (equivalent
to cytokine receptor α-subunit) and CD131, the cytokine β common
(βc) subunit, shared by receptors for GM-CSF, IL-3 and IL-5 [5,9]. On
the contrary, Um et al. [10] reported that the antiapoptotic effect of
Epo in neuronal SH-SY5Y and pheochromocytoma PC-12 cell lines
was primarily mediated by its binding to the “classical” homodimeric
EpoR complex. These authors could not detect βcR expression in
differentiated SH-SY5Y and PC-12 cells.
This lack of agreement on the receptors involved in Epo and cEpo
actions, together with the limited knowledge available to explain
the differential action of cEpo, prompted us to compare Epo and
cEpo activities in neuronal cells (SH-SY5Y cell line) and in cells capa-
ble of erythroid differentiation with different Epo requirements (UT-7
and TF-1). In addition, we investigated signaling pathways involved
in cell activation by Epo in order to explain the differential action of
both erythropoietins.2. Materials and methods
2.1. Materials
All chemicals used were of analytical grade. Alphaminimal essential
medium (alpha-MEM), Dulbecco's modiﬁed Eagle medium (D-MEM),
Ham F12 medium, and Iscove's modiﬁed Dulbecco's medium (IMDM)
were obtained from GibcoBRL. Bovine serum albumin (BSA), 3,4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), sodium
o-vanadate, phenylmethylsulfonylﬂuoride (PMSF), aprotinin, leupeptin,
pepstatin A, staurosporine (STP), Hoechst 33258 dye, methylcellulose,
dimethylsulfoxide (DMSO), and propidium iodide (PI) were obtained
from Sigma-Aldrich; Cytoﬁx/Cytoperm, Perm Wash, Annexin V-FITC
apoptosis detection Kit II, and puriﬁed mouse antihuman-PARP anti-
body were from BD Transduction Laboratories; anti-βactin (sc-47778),
anti-Epo-R (M-20 sc-697), and anti-β-common (IL-3/IL-5/GM-CSFRβ
sc-21765) antibodies were from Santa Cruz Biotechnology. Anti-
phosphorylated FOXO3a, anti-FOXO3a, and anti-phosphorylated Jak2
antibodies were from Cell Signaling Technology. Nitrocellulose (NC)
membranes (Hybond) and chemiluminescent system kit (ECL) were
from Amersham Bioscience; acrylamide/bis-acrylamide solution and
sodium potassium cyanate were from Merck; fetal bovine serum (FBS,
Bioser) and penicillin–streptomycin (PAA Laboratories) were from
GENSA; and Ly294002 and AG490 were obtained from Calbiochem.
Recombinant human erythropoietin (rhEpo) was kindly supported by
Zelltek (Argentina).2.2. Preparation of cEpo
Carbamylated erythropoietin (cEpo) was prepared as described
by Leist et al. [5] with modiﬁcations. Brieﬂy, one volume of Epo
(0.5 mg/ml) was mixed with one volume of 1 M sodium borate
(pH 8.8) and one volume of 3 M potassium cyanate (KCNO). The
mixture was incubated at 37 °C for 48 h. Samples were dialyzed
against milli-Q water during 72 h (4 °C) with frequent changes of
liquid, and then concentrated by Centricon (Millipore, 10 kDa cut-off).
The decrease in the number of free amino groups measured by its reac-
tionwith 2,4,6-trinitrobenzenesulfonic acid [11] was used to determine
the efﬁciency of carbamylation.
Carbamylation of Epo leads to the transformation of lysine residues
into homocitrulline. Therefore, characterization of cEpo, analyzed by gel
electrophoresis under alkaline non-denaturing conditions and immu-
noblotting, displayed increased electrophoretic mobility of cEpo with
respect to Epo, which is explained by the increase in net electric charge
of the molecule.2.3. Clonal assay of hematopoietic progenitors
Femoral bone marrow cells, obtained from Balb/c mice, were
ﬂushed into alpha-MEM containing 2% heat inactivated FBS and
cell suspensions were obtained by gentle pipetting. Cultures were
performed in semisolid medium as previously described [12,13].
Brieﬂy, 5 × 105 cells/ml were stimulated with 5 U/ml Epo in a
mixture containing alpha-MEM, 0.8% methylcellulose medium, 25%
heat inactivated FBS, 2 mM L-glutamine, antibiotics (100 U/ml
penicillin–100 g/ml streptomycin), and 0.1 mM 2-mercaptoethanol.
Cultures were incubated at 37 °C for 48 h, in an atmosphere containing
5% CO2 and 100% humidity. Erythroid colonies were stained with
2,7-diaminoﬂuorene–3% H2O2 in 50 mM Tris–HCl buffer, pH 7.6. Small
erythroid colonies consisting of eight or more hemoglobinized cells
were considered as CFU-E and counted under 400× magniﬁcation
using an inverted microscope (Zeiss Axiovert 135). Geometric means
of CFU-E triplicate cultures were calculated for each assay and
expressed per 5 × 105 mononuclear cells.2.4. Cell lines and cultures
a) HumanUT-7 cell line, kindly provided byDr. PatrickMayeux (Cochin
Hospital, Paris, France), shows growth dependence on Epo. These
cells were maintained in IMDM supplemented with 10% FBS,
100 U/ml penicillin, 100 μg/ml streptomycin, and 2 U/ml Epo [14].
b) Human TF-1 cells (CRL-2003, American Type Culture Collection,
ATCC) are completely dependent on interleukin 3 (IL-3) or
granulocyte-macrophage colony-stimulating factor (GM-CSF)
for long term growth. They can also be stimulated by Epo for
short periods (less than 7 days). TF-1 cells were maintained in
RPMI-1640 medium supplemented with 10% FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin, 2.5 μg/ml anfotericin, and
4 ng/ml GM-CSF [15].
c) Human SH-SY5Y neuroblastoma cells (CRL-2266, ATCC) were
grown in 5 ml of 1:1 D-MEM:Ham F12 supplemented with 2 mM
L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 10%
(v/v) heat-inactivated FBS [16,17].
Cell cultures were developed at 37 °C in an atmosphere containing
5% CO2 and 100% humidity. The mediumwas routinely replaced every
2–3 days. Cell viability and proliferation were evaluated by Trypan
blue exclusion test and the MTT assay.
Erythroid differentiation of UT-7 and TF-1 cells was induced by
30 μM hemin during 48 h while SH-SY5Y cells were differentiated
by treatment with 10 μM retinoic acid (RA) during 4 days.
STP, LY294002, and AG490, dissolved in DMSO, were added to com-
plete medium and adjusted to ﬁnal concentrations as referred below in
text and ﬁgures. The vehicle DMSO was added to controls.
Neutralizing antibodies anti-Epo-R and anti-β-commonwere added
to cultures at 400 ng/ml ﬁnal concentration.2.5. MTT assay
Cells were cultured in 35 mm Petri dishes at a density of
2 × 105 cells/ml. After the cells had been subjected to appropriate
treatments and the medium removed, they were incubated at 37 °C
with MTT at a ﬁnal concentration of 0.5 mg/ml. The supernatant
was removed and the pellet washed with phosphate buffer saline
(PBS). Finally, 100 μl of 0.04 M HCl in isopropanol was added to dis-
solve the blue formazan product (reduced MTT), which was quanti-
ﬁed by measuring the absorbance at 570 nm test wavelength and
655 nm reference wavelength in a microplate reader (BioRad).
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Cells were cultured on slide covers plated in 35 mm Petri dishes.
After ﬁxing with 4% (v/v) p-formaldehyde in PBS for 20 min at
room temperature, the samples were exposed to 0.05 g/l Hoechst
33258 dye in PBS for 10 min at room temperature, washed thrice
with 18 MΩ water and ﬁnally mounted by using 50% glycerol in PBS
(v/v). Fluorescent nuclei with apoptotic characteristics were detected
by microscope under UV illumination at 365 nm (Zeiss Axiovert 135).
Images were photographed by a Nikon Coolpix 5000 equipment and
digitalized. Differential cell counting was performed by analyzing at
least 500 cells [17].
2.7. Electrophoresis and Western blotting
Cell were washed with ice-cold PBS and lysed with hypotonic buffer
(50 mM TRIS pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 mM sodium
o-vanadate) containing protease inhibitors (1 mMPMSF, 4 μMleupeptin,
1 μg/ml aprotinin, 2 μM pepstatin) in a ratio of 200 μl/107 cells. After
30 min of incubation on ice, insolublematerial was removed by centrifu-
gation (15,000 g, 15 min). Cell extracts were boiled for 3 min in the
Laemmli sample buffer [18] and resolved on 10% polyacrylamide-SDS
gel electrophoresis. Electrophoresis under nondenaturing conditions
was run in a Miniprotean III electrophoretic system (BioRad) using
10% polyacrylamide gels. After electrophoresis, protein samples were
electroblotted onto nitrocellulose membrane during 1.5 h (transfer
buffer: pH 8.3, 25 mM Tris, 195 mM glycine, 0.05% SDS, pH 8.3, and
20% (v/v) methanol). Membranes were blocked by 1 h-incubation in
Tris buffer saline (25 mM Tris, 137 mM NaCl, 3 mM KCl, pH 7.4)
containing 0.1% Tween 20 and 0.5% skim-milk powder, and then incu-
bated with appropriate concentrations of speciﬁc antibodies. After wash-
ing with TBS–0.1% Tween 20, the immunoblots were probed with
adequate peroxidase-conjugated secondary antibody (1:1000) for 1 h
at 20 °C and washed. Antigen–antibody complex signals were detected
by enhanced chemiluminescence, using ECL kit and a Fujiﬁlm Intelligent
Dark Box II equipment (Fuji) coupled to a LAS-1000 digital camera.
Anti-β-actin polyclonal antibody was used to assess sample loading
variations. Densitometry with ImageGauge software was performed to
quantify the bands.
2.8. Flow cytometry
2.8.1. Jak2 phosphorylation
After experimental treatments, cells were collected by centrifuga-
tion and washed with 2% FBS in PBS. Then, cells were incubated with
Cytoﬁx–Cytoperm for 20 min, and following centrifugation (350 g,
10 min) they were incubated with anti-phosphorylated Jak2 antibody
(30 min, 4 °C) and washed with Perm Wash. After that, Alexa Fluor
488-second antibody incubation (30 min, 4 °C) was made and ﬁnally,
samples were analyzed in a ﬂow cytometer equipped with a 488 nm
argon laser (FACSort, Becton-Dickinson). WinMDI 2.9 software was
used to analyze data.
2.8.2. Annexin V binding and propidium iodide analysis
At the end of treatments, the cells were washed with binding
buffer and then incubated with Annexin V and propidium iodide
(15 min at room temperature in the dark), according to the
manufacturer's indications. After this period, cultures were washed
with binding buffer and ﬁnally, the samples were mounted and ana-
lyzed by ﬂow cytometry as described above.
2.8.3. Cell cycle analysis
After UT-7 cells (5 × 105 cells/ml) were subjected to appropriate
treatments, they were harvested by centrifugation, washed twice with
PBS, and ﬁxed with 70% ethanol at 4 °C overnight. Then the cells were
washed with PBS. The DNA of ethanol-ﬁxed cells was stained bypropidium iodide (0.5 mg/ml) containing RNase A (120 μg/ml) at
37 °C for 60 min. The cell cycle distribution for single cells was carried
out using ﬂow cytometry [19].
2.9. Statistics
Results are expressed as mean ± standard error (mean ± SEM).
Comparison among groups was carried out by the Kruskal–Wallis
one-way analysis of variance and the Mann–Whitney U-test when
corresponding. Least signiﬁcant difference with P b 0.05 was consid-
ered as the criterion for statistical signiﬁcance.
3. Results
3.1. Comparison between the effects of erythropoietin and its carbamylated
derivative upon erythroid and neuronal cells
Firstly, we have to demonstrate that the prepared carbamylated
erythropoietin (cEpo) has neuroprotective but not erythropoietic
ability. In order to do that we made cultures of the SH-SY5Y cell
line from neuronal origin and of cells with a capacity for erythroid
differentiation (physiological murine CFU-E and human UT-7 and
TF-1 cell lines). Since Epo has long been considered a speciﬁc
apoptosis-preventing trophic factor which allows erythroid cells
to fulﬁll their program of proliferation and differentiation [20], we
evaluated the differential antiapoptotic effects between Epo and
cEpo.
It can be seen in Fig. 1 that Epo, but not cEpo, signiﬁcantly stimu-
lated progenitor cells from murine bone marrow leading to the ap-
pearance of CFU-E (Fig. 1A) and maintained the survival of cells
from UT-7 and TF-1 lines with a capacity for erythroid differentiation
(Fig. 1B and C).
Interestingly, Epo and cEpo simultaneously added to cultures at 1:10
ratio completely inhibited CFU-E growth, suggesting cEpo interference
with the proliferative effect of Epo (Fig. 1A). This yet unreported ﬁnding
which was not observed when cEpo was added after 60 min of Epo
stimulation supports the concept that cells are fully activated by Epo
within this period.
Quite opposite was the action of cEpo upon SH-SY5Y cells of neu-
ronal origin induced to apoptosis by staurosporin (STP), which had
been previously demonstrated to be overcome by Epo [17]. Before
the addition of the proapopotic agent, cells were preincubated in
the presence of Epo or cEpo. Fig. 1D shows that both erythropoietins
have similar neuroprotective effects since they completely prevented
STP-induced apoptosis. Moreover, we add new information about
mechanisms of this neuroprotective action. The fact that prevention
of programmed cell death by Epo or cEpo was mediated by PI3K
and Jak2 signaling pathways in assays with Ly294002 (PI3K inhibitor)
and AG490 (Jak2 inhibitor), suggests similar mechanisms for Epo and
cEpo neuroprotection (Fig. 1D).
Similar results between Epo and cEpo were observed when apo-
ptosis of SH-SY5Y cells was induced by the proinﬂammatory cytokine
tumor necrosis factor (data not shown).
3.2. Erythropoietin and beta-common receptors in erythroid and neuronal
cell lines
Current knowledge supports the idea that two different receptors,
the homodimer EpoR–EpoR and the heterodimer EpoR–βcR, may be
involved in the action of Epo and cEpo. We therefore investigated
the expression of both receptors in erythroid and neuronal cells
under different stages of cell differentiation.
Unlike SH-SY5Y cells differentiated by retinoic acid, undifferenti-
ated cells showed the expression of EpoR and βcR. On the other
hand, regardless of their differentiation stage, cells with erythroid
Fig. 1. Effects of erythropoietin and carbamylated erythropoietin on erythroid progenitors and different cell lines. A) Murine bone marrow cells (5 × 105/ml) were stimulated with
20 ng/ml of either Epo (E) or cEpo (cE) for 48 h. CFU-E development was determined by colony count under microscope after reaction with 2,7-diaminoﬂuorene. Unlike Epo,
cEpo did not induce signiﬁcant CFU-E growth (***P b 0.001, n = 10). In competition assays, CFU-E growth was decreased at levels of cultures performed without Epo only
when 200 ng/ml cEpo concentration (cEpo 10×) was simultaneously added with Epo to the cultures. This cEpo interference disappeared when it was added 60 min after Epo
stimulation had started (***P b 0.001, n = 10). B–C) UT-7 cells were incubated with 20 ng/ml Epo or 20 ng/ml cEpo for 48 h. After 18 h-starvation (without GF), TF-1 cells
were cultured with 4 ng/ml GM-CSF (GM) or 20 ng/ml of either Epo or cEpo. Apoptosis was evaluated by ﬂuorescence microscopy after Hoechst stain, Western blotting of PARP
degradation (indicated by the appearance of the 85 kDa b-band; β-actin: internal control of protein loading), and Annexin V binding to phosphatidylserine. In UT-7 and TF-1
cultures, Epo but not cEpo prevented apoptosis (***P b 0.001, **P b 0.01, *P b 0.05; n = 6). D) SH-SY5Y neuronal cells were cultured in the presence of 100 ng/ml of either Epo
or cEpo during 24 h and then, exposed to 50 nM STP (24 h). In assays with 25 μM Ly294002 or 25 μM AG490, the inhibitors were added 2 h before the addition of Epo or cEpo.
Apoptosis induced by STP (**P b 0.01, n = 5) was prevented by pretreatment with either Epo or cEpo while these protective effects were abrogated by the presence of Ly and
AG (**P b 0.01, n = 3). Each bar represents mean ± SEM of the indicated independent assays.
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(Fig. 2A).
As a consequence of the binding of an appropriate ligand to each
of the EpoR–EpoR or the EpoR–βcR dimers, cell activation is initiatedby Jak2 phosphorylation. Therefore, this mechanism was evaluated in
cell cultures performed in the presence of both inducers. As expected,
Epo and cEpo induced Jak2 phosphorylation in SH-SY5Y cells (Fig. 2B).
Interestingly, cEpo also induced Jak2 phosphorylation in TF-1 and
Fig. 2. Expression of EpoR and βcR under different stages of cell differentiation.
A) TF-1 and UT-7 cells were subjected to erythroid differentiation by 30 μM hemin
during 48 h (H) while differentiation of neuronal SH-SY5Y cells was achieved by
retinoic acid (10 μM RA, 4 days). Cell extracts were resolved by SDS-PAGE (T = 10%),
electroblotted on a NC membrane and then immunodetected by chemiluminescence
using speciﬁc antibodies. Each bar represents mean ± SEM of band density with respect
to β-actin, used as control of sample loading. B) SH-SY5Y cell incubations with 250 ng/ml
of either Epo (E) or cEpo (cE) for 10 min and p-Jak2 analyzed by ﬂow cytometry. C) After
18 h without growth factors, TF-1 cells were incubated with 20 ng/ml Epo or 20 ng/ml
cEpo during 10 min and p-Jak2 was detected. D) UT-7 cell cultures were incubated with
20 ng/ml of either Epo or cEpo (10 min) to determine Jak2 phosphorylation (p-Jak2).
Each bar represents mean ± SEM. Signiﬁcant differences of ﬂuorescence intensity:
**P b 0.01; * P b 0.05 (n = 3).
Fig. 3. Receptors involved in the Epo and cEpo actions on neuronal cells. A) SH-SY5Y
cells were incubated in the presence of anti-EpoR (EpoR Ab) or anti-βcR (βcR Ab)
antibodies during 2 h before the addition of Epo or cEpo. After 24 h, cells were exposed
to 50 nM STP for an additional 24 h. Percentage of apoptotic cells was determined by
ﬂuorescence microscopy after Hoechst stain. The presence of neutralizing antibodies
(400 ng/ml) completely blocked the neuroprotective effect of cEpo (**P b 0.01; n = 3).
Anti-EpoR prevented the action of Epo (**P b 0.01, n = 3) while anti-βcR only blunted
the Epo effect (*P b 0.05, n = 3). B–C) SH-SY5Y cells, pretreated for 24 h with Epo or
cEpo (20 ng/ml) in the presence or absence of GM-CSF (40 ng/ml), were exposed to
50 nM STP for an additional 24 h. Apoptosis was evaluated by differential count of
apoptotic nuclei (B: ﬂuorescence microscopy) and by phosphatidylserine translocation
(C: ﬂow cytometry analysis). GM-CSF, which was not toxic for the cells, did not prevent
the STP-induced apoptosis (GM-CSF-STP vs. STP, NS) but blocked the protective action
of cEpo (**P b 0.01, *P b 0.05, n = 3).
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and D), even though cEpo did not support cell survival. This ﬁnding
was conﬁrmed in UT-7 culture assays with neutralizing anti-EpoR
and anti-βcR antibodies which prevented the cEpo induction of
Jak2 phosphorylation (data not shown).
3.3. Receptors involved in the action of erythropoietin and
carbamylated erythropoietin
Different authors reported that Epo neuroprotective action would
be mediated by the heterodimeric receptor (EpoR–βcR) [5,6,21,22].On the other hand, it is known that TF-1 cells are dependent on
GM-CSF to survive and that the speciﬁc receptor of this factor in-
volves the βc receptor subunit.
Results obtained so far suggest that Epo and cEpo have similar
behavior upon neuronal SH-SY5Y cells. Nevertheless, Epo and cEpo
show differential action upon TF-1 cells capable of erythroid differen-
tiation. We consequently decided to carry out assays of competition
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of Epo and cEpo with both cell lines.
Epo and cEpo neuroprotective effects against STP-induced apoptosis
in undifferentiated SH-SY5Y cells were analyzed in the presence of
400 ng/ml neutralizing anti-EpoR or anti-βcR antibodies (Fig. 3A).
The neuroprotective action of Epo against STP–induced apoptosis was
completely blocked in the presence of anti-EpoR and only blunted by in-
cubationwith anti-βcR antibody. In contrast, treatment of cultureswith
each antibody completely prevented the antiapoptotic action of cEpo.
These results agree with those of cells grown in the presence of
GM-CSF, which competes for the binding to βcR (Fig. 3B). It has to be
noted that the high concentration of GM-CSF used in this assay did
not induce cell apoptosis.
This evaluation of programmed cell death obtained by detection of
ﬂuorescent nuclei after Hoechst stain strongly agreed with results of
analysis of other sign of apoptosis, such asmembranephosphatidylserine
translocation detected by Annexin V binding and propidium iodide
nucleus stain (Fig. 3C).
Regarding TF-1 cells, we found that high concentrations of cEpo
blocked the antiapoptotic action of GM-CSF and partially affected
the Epo activity (Fig. 4).
The results shown in Figs. 3 and 4 suggest that in neuronal cells
Epo acts via both, the homodimeric and the heterodimeric receptors
whereas cEpo only binds to the latter. However, cEpo is also able
to interact with TF-1 cells, which can explain Jak2 phosphorylation
induced by cEpo in this cell line.Fig. 4. Receptors involved in the Epo and cEpo actions on erythroid cells. After deprivation
of growth factors for 18 h, TF-1 cells were cultured in the presence of Epo (20 ng/ml),
cEpo (20 ng/ml) or GM-CSF (4 ng/ml) during 24 h. In other assays, Epo or GM-CSF
were simultaneously addedwith low (20 ng/ml) or high (200 ng/ml) cEpo concentration.
Analysis of apoptosis by ﬂuorescence microscopy (A) and ﬂow cytometry (B) revealed
partial interference of cEpo with cell protection by Epo and complete interference with
the action of GM-CSF. Each bar represents mean ± SEM. Signiﬁcant differences
***P b 0.001, **P b 0.01, *P b 0.05 (n = 3).
Fig. 5. Erythropoietin and carbamylated erythropoietin on events of cell proliferation.
A–B)UT-7 cellswere incubatedwith 20 ng/ml Epoor 20 ng/ml cEpo. After 18 h-starvation
(Without GF), TF-1 cells were cultured with 4 ng/ml GM-CSF (GM) or 20 ng/ml of either
Epo or cEpo. Cultures were performed for 30 min to analyze FOXO3a phosphorylation or
24 h for p27kip1 detection by Western blotting. Blots are representative of 3 assays. Each
bar represents mean ± SEM of band density with respect to β-actin. Unlike Epo, cEpo
was incapable of inducing phosphorylation of FOXO3a, thus leading to p27kip1 expression
(**P b 0.01, *P b 0.05, n = 3). C) After incubation with Epo or cEpo for 24 h, UT-7 cells
were assayed for DNA content by PI staining and ﬂow cytometry. Histograms indicating
percentage of cellswith respect to ﬂuorescence intensity (DNA content) are representative
of 4 independent experiences. Each bar corresponds to positive cells in each cell cycle
phase (**P b 0.01, N.S.: nonsigniﬁcant, n = 4).
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proliferation signaling
This work suggests that differential behavior of Epo and cEpo in ery-
throid cells seems to be principally related to cell proliferation. Based on
results of Jak2 activationwhich conﬁrmed the interaction of both eryth-
ropoietins with erythroid cells, it was interesting to investigate events
associated to cell cycle and proliferation. Downstream targets of Epo
have been shown to regulatemechanismswhichhave signiﬁcant effects
on hematopoietic cell proliferation under physiological conditions.
Therefore, we analyzed phosphorylation of the forkhead transcription
factor FOXO3a and expression of p27kip1 in TF-1 and UT-7 cells stimu-
lated by Epo or cEpo. As can be seen in Fig. 5(A and B), activation of
cells by Epo led to phosphorylation of FOXO3a whereas this event
could not be induced by cEpo. This factor is a known regulator of
genes, such as p27, thus affecting cell cycle progression. In accordance
with this, p27kip1 levels in cell cultures treated with cEpo were similar
to those observed in non-activated cells (Fig. 5A, B). These results are
consistent with the involvement of cEpo in slowing down G1 to S pro-
gression in comparison with the effect of Epo on UT-7 cell cycle (Fig. 5C).
It was interesting to study p27kip1 expression in neuronal SH-SY5Y
cells, which are not dependent on Epo or cEpo to proliferate. In this
cell line, neither Epo nor cEpo induced changes in p27kip1 levels
with respect to non-treated controls (data not shown).
We can conclude that FOXO3a inactivation and p27kip1 expression
induced by cEpo is compatible with cell cycle arrest, and consequently,
restrains cell proliferation.
4. Discussion
The results obtained from different in vitro assays included in this
work agree with the concept that carbamylation of Epo lysine resi-
dues leads to a derivative that retains the ability of Epo to protect
neuronal cells against apoptosis induced by STP or TNF-α while it is
unable to support erythroid cell proliferation.
Interestingly, our unexpected ﬁnding was that – similarly to its
effect on neuronal cells – cEpo induced Jak2 phosphorylation in UT-7
and TF-1 cells despite its incapacity to act as a growth factor in these
cell lines. This suggests that the interaction between cEpo and erythroid
cells involves a receptorwhich belongs to the type I cytokine superfamily.
After the initial study by Masuda et al. [23], it is currently as-
sumed that the Epo receptor involved in non-hematopoietic tissue
protection is different from that participating in signal transduction
in the hematopoietic system. Based on different observations, the
heterodimeric receptor formed by the EpoR and βcommonR sub-
units was hypothesized to play a role in the antiapoptotic action of
Epo [24,25]. Alternatively, other studies support the notion that at
least in some types of neuronal cells the cytoprotective effects of
Epo are mediated by the “classical” homodimeric EpoR complex, in
a similar way as Epo exerts its antiapoptotic and proliferative effects
on erythroid cells. Data from an in vivo experiment suggest that most
neurons in the rat brain are likely to express high levels of EpoR but
low, if not null, levels of βcR [26]. Likewise, Um et al. [10] reported
that differentiated SH-SY5Y cells do not express a detectable level
of βc receptor, even though Epo was able to speciﬁcally bind to
high-afﬁnity Epo surface binding sites on these cells and to exert
neuroprotective activity. In this work, we have also found an
undetectable βc subunit in SH-SY5Y cells induced to differentiation
with retinoic acid (Fig. 2). Instead, both receptors, EpoR and βcR, were
found expressed in undifferentiated SH-SY5Y and in undifferentiated
or erythroid differentiated UT-7 and TF-1 cell lines. The ﬁnding of
EpoR and βcR in all cell lines used in this study let us design inhibition
experiments with neutralizing antibodies and competition assays be-
tween cEpo and other speciﬁc ligands. Considering that βc is also a
subunit involved in the GM-CSF receptor, this growth factor was chosen
for competition assays. In SH-SY5Y cell cultures, STP-induced apoptosiscould not be prevented by cEpo in the presence of GM-CSF or by theβcR
inhibition with speciﬁc antibodies (Fig. 3). In a reverse experiment,
GM-CSF failed to support TF-1 cell growth in the presence of high
cEpo concentration (Fig. 4). While further investigation is needed to
fully clarify this possibility, our results suggest an interaction between
cEpo and the EpoR and βcR subunits, therefore hinting at its binding
to the heterodimeric receptor EpoR/βcR in both cell lines. This ﬁnding
may explain why cEpo competes with the proliferative action of Epo
upon murine CFU-E since we demonstrated that cEpo, at tenfold con-
centration (200 ng/ml) with respect to Epo (20 ng/ml), interferes
with the stimulation of colony growth by the latter erythropoietin
(Fig. 1). The fact that this interference is not observed when cells are
stimulated with Epo prior to the addition of cEpo is not unexpected,
as a previous study showed that inhibition of CFU-E growth by alumi-
num only occurred in the presence of Epo at early stages (less than
60 min) during the interaction of the hormone with its target cell
[12]. It is known that activation of the EpoR after Epo binding is tran-
sient as EpoR appears to be quickly degraded after ubiquitination by
two proteolytic systems that proceed successively: the proteasomes
remove part of the intracellular domain at the cell surface, and the
lysosomes degrade the remaining part of the receptor–hormone com-
plex [27].
On the other hand, it seems that Epo may act through both, the
homodimeric (EpoR/EpoR) and the heterodimeric (EpoR/βcR) recep-
tors in neuronal SH-SY5Y cells and probably in an erythroid cell type
as well. This ﬁnding was not unexpected because as early as 1995 Epo
was reported to induce the tyrosine phosphorylation of βcR in UT-7
cells [24].
This dual binding capacity of Epo probably depends on the density of
the receptor subunits. Thus, EpoR may either self-associate to form
EpoR/EpoR or participate in the complex EpoR/βcR which can also sup-
port signaling. cEpo can only bind to the heteroreceptor in SH-SY5Y
cells. Additionally, cEpo binding to the EpoR/βcR in TF-1 cells probably
explain Jak2 phosphorylation in these cell lines.
In a review discussing the structure of βcR, special note was made
of an ongoing debate regarding the activation mechanisms of more
complicated class I cytokine receptors in which the receptor systems
contain a shared receptor subunit. The authors mentioned the βc
subunit of the IL-3, IL-5 and GM-CSF receptors as examples [28] and
it is likely that the complex formed by EpoR and βcR can also be a
case in point.
The UT-7 and TF-1 cells have been included in this work because
both cell lines are stimulated by Epo but they have different depen-
dence on the growth factor. This difference may be explained by the
type of EpoR expressed in both cell lines. Chrètien et al. [29] reported
that TF-1 cells, which overexpress a truncated EpoR, showed an im-
paired activation of the STAT5 transcription factor when they are
stimulated by Epo. However, the EpoR structure in different cells is
still open to investigation. Human bone marrow cells express trun-
cated and full-length forms of EpoR being the former predominating
in immature progenitors and the latter in the late-state progenitors
[30]. In different tissues Arcasoy et al. [31] found the expression of
EpoR splice variants encoding peptides that are truncated in the
carboxy-terminal region of the intra-cytoplasmic domain. Following
this paper we investigated these EpoR transcripts in different lines
and observed similar expression patterns between UT-7 and TF-1
[unpublished data]. Whether the presence of EpoR isoforms is related
with different cell stimulation by Epo remains to be determined.
Nevertheless, this point seems not to be relevant to explain differ-
ences between Epo and cEpo action since in the present work we
demonstrated similar behavior upon UT-7 and TF-1 cells.
The ability of cEpo to bind toβcR in TF-1 cells and the ﬁnding of UT-7
and TF-1 cell activation by cEpo detected by Jak2 phosphorylation
(Fig. 2) prompted us to further investigate the step at which the action
of the modiﬁed erythropoietin differs from that of the native Epo. Jak2
phosphorylation is generally important in transmitting signals from
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antiapoptotic property of Epo without its ability to promote cell
proliferation, we analyzed factors involved in cell growth, such as
FOXO3a and p27kip1. The activity of FOXO3a, which belongs to the
FOXO family of transcription factors, is negatively regulated by the
PI3K/Akt cascade, a signaling pathway activated by Epo. Akt can
phosphorylate FOXO3a and promote its cytoplasmatic accumulation
[32] with decreased transcription of the target genes, among which
p27kip1 is known to be a key molecule that modulates cell cycle
[19]. Therefore, it was also interesting to study cell cycle in cell
cultures stimulated either by Epo or by cEpo. Cultures in the pres-
ence of Epo increased cell number at S phase, showing that it could
promote the G1-S transition whereas cEpo induced cell arrest at
G0–G1 phase (Fig. 5). These results are in line with those showing
Epo-induced FOXO3a phosphorylation and p27kip1 downregulation.
It has been reported that Epo controls the phosphorylation of
FOXO3a via the PI3K/Akt signaling pathway and its degradation to
retain it in the cytoplasm through binding to 14-3-3 protein [33].
Phosphorylated FOXO3a does not translocate to the nucleus, and is
consequently unable to stimulate the expression of p27kip1, thus
allowing the progression of the cell cycle and cell proliferation.
In contrast, in cell cultures with cEpo cell cycle progression at the
G1/S transition was inhibited, probably due to the translocation of
the unphosphorylated forkhead factor FOXO3a to the nucleus and
its upregulation of the cyclin-dependent kinase inhibitor p27kip1
(Fig. 5).
Present results may explain those reported by Ramirez et al. [34]
who found phosphorylation of the antiapoptotic Jak2/Akt signal in
UT-7 cells induced by carbamylated darbepoietin but had a marginal
effect on cell proliferating signals (Erk1/2, NF-κB and Stat-5) in en-
dothelial progenitor cells. Our results went forward to downstream
signals, conﬁrming that cEpo failed to activate signaling pathways
of cell proliferation.
Regarding neuronal cells, we observed similar Jak2 and PI3K-
mediated mechanisms of the antiapoptotic actions of Epo and cEpo,
although cEpo seems to bind to the heterodimeric receptor and Epo
may do it to both, the EpoR/EpoR and EpoR/βcR (Fig. 3). A mecha-
nism of cEpo action mediated by PI3K/Akt was also reported regard-
ing cardioprotection [35].
The similar Epo and cEpo activities found in ourwork upon SH-SY5Y
cells as well as p27kip1 levels after activation of these cells by Epo or
cEpo are not unexpected given that cEpo keeps its antiapoptotic ability
and the SH-SY5Y neuronal cell line does not depend on these growth
factors to proliferate.
In conclusion, herewe present an advance to elucidate differential ef-
fects between Epo and cEpo uponhematopoietic and non-hematopoietic
cells since for the ﬁrst time we report the inability of the carbamylated
erythropoietin to completely activate signaling pathways focused to
cell proliferation. Finally, we suggest that Epo may activate neuronal
cells through both receptors, the homodimer and the heterodimer,
whereas cEpo may only bind to the heterodimer EpoR/βcR. This means
that only cells which express EpoR and βcR would be potentially targets
for the cEpo antiapoptotic activity leading to a reduced degree of tissue
damage. In addition, precise focus upon interference of high doses of
cEpo with Epo and GM-CSF is required to elucidate beneﬁts and risks
of future therapeutic strategies.
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